Biomedical Engineering Reference
In-Depth Information
by a 2-phenylaminopyrimidine derivative.
Cancer Res
1996; 56(1):
100-104.
86. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes
TP,
Macrophage colony-stimulating factor receptor c-fms is a
novel target of imatinib.
et al.
2005; 105(8): 3127-3132.
87. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition
of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine
kinase inhibitor.
Blood
2000; 96(3): 925-932.
88. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase
activity is inhibited by STI571.
Blood
2001; 97(8): 2440-2448.
89. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S,
Blood
et al.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth
of Bcr-Abl positive cells.
1996; 2(5): 561-566.
90. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD,
Nat Med
et
al.
STI571 inactivation of the gastrointestinal stromal tumor c-KIT
oncoprotein: biological and clinical implications.
Oncogene
2001;
20(36): 5054-5058.
91. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala
P, Tuveson D,
Effect of the tyrosine kinase inhibitor STI571 in a
patient with a metastatic gastrointestinal stromal tumor.
et al.
N Engl J Med
2001; 344(14): 1052-1056.
92. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola
E, Dimitrijevic S,
Safety and efficacy of imatinib (STI571) in
metastatic gastrointestinal stromal tumours: a phase I study.
et al.
Lancet
2001; 358(9291): 1421-1423.
93. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf
W,
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent
for gastrointestinal stromal tumours, but does not yield responses in
other soft-tissue sarcomas that are unselected for a molecular target.
Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II
study.
et al.
2003; 39(14): 2006-2011.
94. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY,
Eur J Cancer
Progression-free survival in gastrointestinal stromal tumours with
high-dose imatinib: randomised trial.
et al.
Lancet
2004; 364(9440): 1127-
1134.
95. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD,
et
al.
Correlation of kinase genotype and clinical outcome in the North
American Intergroup Phase III Trial of imatinib mesylate for treatment
of advanced gastrointestinal stromal tumor: CALGB 150105 Study by
